This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Allan, C. A. Articles by McLachlan, R. I. Search for Related Content PubMed PubMed Citation Articles by Allan, C. A. Articles by McLachlan, R. I. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CHOLESTEROL ESTRADIOL TESTOSTERONE Medline Plus Health Information Hormone Replacement Therapy Related Collections Male Endocrinology Metabolism

Testosterone Therapy Prevents Gain in Visceral Adipose Tissue and Loss of Skeletal Muscle in Nonobese Aging Men

Prince Henry’s Institute (C.A.A., H.G.B., E.A.F., R.I.M.), Andrology Australia (C.A.A., R.I.M.), and Departments of Obstetrics and Gynecology (C.A.A., R.I.M.) and Medicine (B.J.G.S.), Monash University; and Clinical Nutrition and Metabolism Unit (B.J.G.S.), Monash Medical Centre, Monash University, Clayton, Victoria 3168, Australia

Address all correspondence and requests for reprints to: Professor R. I. McLachlan, Prince Henry’s Institute, P.O. Box 5152, Clayton, Victoria 3168, Australia. E-mail: rob.mclachlan{at}princehenrys.org.

Background: Trials of testosterone therapy in aging men have demonstrated increases in fat-free mass (FFM) and skeletal muscle and decreases in fat mass (FM) but have not reported the impact of baseline body composition.

Objective: The objective of the study was to determine the effect, in nonobese aging men with symptoms of androgen deficiency and low-normal serum testosterone levels, of testosterone therapy on total and regional body composition and hormonal and metabolic indices.

Methods: Sixty healthy but symptomatic, nonobese men aged 55 yr or older with total testosterone (TT) levels less than 15 nM were randomized to transdermal testosterone patches or placebo for 52 wk. Body composition, by dual-energy x-ray absorptiometry (FM, FFM, skeletal muscle) and magnetic resonance imaging (abdominal sc and visceral adipose tissue, thigh skeletal muscle, and intermuscular fat) and hormonal and metabolic parameters were measured at wk 0 and 52.

Results: Serum TT increased by 30% (P = 0.01), and LH decreased by 50% (P < 0.001). Relative to placebo, total body FFM (P = 0.03) and skeletal muscle (P = 0.008) were increased and thigh skeletal muscle loss was prevented (P = 0.045) with testosterone therapy and visceral fat accumulation decreased (P = 0.001) without change in total body or abdominal sc FM; change in visceral fat was correlated with change in TT levels (r² = 0.36; P = 0.014). There was a trend to increasing total and low-density lipoprotein cholesterol with placebo.

Conclusion: Testosterone therapy, relative to placebo, selectively lessened visceral fat accumulation without change in total body FM and increased total body FFM and total body and thigh skeletal muscle mass. Further studies are needed to determine the impact of these body compositional changes on markers of metabolic and cardiovascular risk.

This article has been cited by other articles:

				J. J. Carrero, A. R. Qureshi, P. Parini, S. Arver, B. Lindholm, P. Barany, O. Heimburger, and P. Stenvinkel Low Serum Testosterone Increases Mortality Risk among Male Dialysis Patients J. Am. Soc. Nephrol., March 1, 2009; 20(3): 613 - 620. [Abstract] [Full Text] [PDF]

				C. Wang, E. Nieschlag, R. Swerdloff, H. M. Behre, W. J. Hellstrom, L. J. Gooren, J. M. Kaufman, J.-J. Legros, B. Lunenfeld, A. Morales, et al. Investigation, Treatment, and Monitoring of Late-Onset Hypogonadism in Males: ISA, ISSAM, EAU, EAA, and ASA Recommendations J Androl, January 1, 2009; 30(1): 1 - 9. [Full Text] [PDF]

				A. M. Traish, A. Guay, R. Feeley, and F. Saad The Dark Side of Testosterone Deficiency: I. Metabolic Syndrome and Erectile Dysfunction J Androl, January 1, 2009; 30(1): 10 - 22. [Abstract] [Full Text] [PDF]

				A. M. Traish, F. Saad, and A. Guay The Dark Side of Testosterone Deficiency: II. Type 2 Diabetes and Insulin Resistance J Androl, January 1, 2009; 30(1): 23 - 32. [Abstract] [Full Text] [PDF]

				N Sucunza, M J Barahona, E Resmini, J M Fernandez-Real, J Farrerons, P Lluch, T Puig, A M Wagner, W Ricart, and S M Webb Gender dimorphism in body composition abnormalities in acromegaly: males are more affected than females Eur. J. Endocrinol., December 1, 2008; 159(6): 773 - 779. [Abstract] [Full Text] [PDF]

				C Wang, E Nieschlag, R Swerdloff, H M Behre, W J Hellstrom, L J Gooren, J M Kaufman, J-J Legros, B Lunenfeld, A Morales, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations Eur. J. Endocrinol., November 1, 2008; 159(5): 507 - 514. [Full Text] [PDF]